Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Antoine Leuzy, Ruben Smith, Rik Ossenkoppele, et al.
JAMA Neurology (2020) Vol. 77, Iss. 8, pp. 955-955
Open Access | Times Cited: 180

Showing 1-25 of 180 citing articles:

Alzheimer disease
David S. Knopman, Hélène Amieva, Ronald C. Petersen, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 1528
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
Sebastian Palmqvist, Shorena Janelidze, Yakeel T. Quiroz, et al.
JAMA (2020) Vol. 324, Iss. 8, pp. 772-772
Open Access | Times Cited: 965
Biomarkers for neurodegenerative diseases
Oskar Hansson
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 954-963
Open Access | Times Cited: 743
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Jacob W. Vogel, Alexandra L. Young, Neil P. Oxtoby, et al.
Nature Medicine (2021) Vol. 27, Iss. 5, pp. 871-881
Open Access | Times Cited: 551
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
Nicholas J. Ashton, Tharick A. Pascoal, Thomas K. Karikari, et al.
Acta Neuropathologica (2021) Vol. 141, Iss. 5, pp. 709-724
Open Access | Times Cited: 473
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Sebastian Palmqvist, Pontus Tideman, Nicholas Cullen, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 1034-1042
Open Access | Times Cited: 370
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Giovanni B. Frisoni, Daniele Altomare, Dietmar Rudolf Thal, et al.
Nature reviews. Neuroscience (2021) Vol. 23, Iss. 1, pp. 53-66
Open Access | Times Cited: 337
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 282
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
Thomas K. Karikari, Andréa Lessa Benedet, Nicholas J. Ashton, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 2, pp. 429-442
Open Access | Times Cited: 273
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
Shorena Janelidze, David Berron, Ruben Smith, et al.
JAMA Neurology (2020) Vol. 78, Iss. 2, pp. 149-149
Open Access | Times Cited: 270
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2381-2387
Open Access | Times Cited: 265
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Joel Simrén, Antoine Leuzy, Thomas K. Karikari, et al.
Alzheimer s & Dementia (2021) Vol. 17, Iss. 7, pp. 1145-1156
Open Access | Times Cited: 260
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Rik Ossenkoppele, Ruben Smith, Niklas Mattsson, et al.
JAMA Neurology (2021) Vol. 78, Iss. 8, pp. 961-961
Open Access | Times Cited: 228
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari, Nicholas J. Ashton, Gunnar Brinkmalm, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 7, pp. 400-418
Closed Access | Times Cited: 213
High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies
Kenji Tagai, Maiko Ono, Manabu Kubota, et al.
Neuron (2020) Vol. 109, Iss. 1, pp. 42-58.e8
Open Access | Times Cited: 208
Challenges and hopes for Alzheimer’s disease
Suren A. Tatulian
Drug Discovery Today (2022) Vol. 27, Iss. 4, pp. 1027-1043
Closed Access | Times Cited: 201
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Che-Wei Chang, Qiang Shao, Lennart Mucke
Science (2021) Vol. 371, Iss. 6532
Open Access | Times Cited: 194
Tauopathies: new perspectives and challenges
Yi Zhang, Kaimin Wu, Yang Liu, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 187
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Niklas Mattsson, Shorena Janelidze, Randall J. Bateman, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 6
Open Access | Times Cited: 153
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
Nicholas Cullen, Antoine Leuzy, Sebastian Palmqvist, et al.
Nature Aging (2020) Vol. 1, Iss. 1, pp. 114-123
Closed Access | Times Cited: 144
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Nicholas J. Ashton, Andréa Lessa Benedet, Tharick A. Pascoal, et al.
EBioMedicine (2022) Vol. 76, pp. 103836-103836
Open Access | Times Cited: 122
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
Maurits Johansson, Erik Stomrud, Philip S. Insel, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 114
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Gemma Salvadó, Rik Ossenkoppele, Nicholas J. Ashton, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 5
Open Access | Times Cited: 110
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
Alexa Pichet Binette, Nicolai Franzmeier, Nicola Spotorno, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 87
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
Shorena Janelidze, Nicolas R. Barthélemy, Yingxin He, et al.
JAMA Neurology (2023) Vol. 80, Iss. 5, pp. 516-516
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top